Oncologists often use the phrase “clinically meaningful benefit” to describe the effect of an experimental treatment. But is the benefit meaningful for patients? A new paper suggests that benefit claims in journal articles often fall short.
From basic science to survivorship and patient advocacy, the OHSU Knight Cancer Institute’s ‘Cancer translated’ blog explores new ideas and debates in cancer medicine. We sorted a year’s worth of posts to find the most heavily trafficked reports. Here are the top 10 in order of popularity:
Gordon Mills, M.D., Ph.D., the new director of precision oncology at Oregon Health & Science University, outlines his vision for the field Gordon Mills, M.D., Ph.D. (OHSU/Kristyna Wentz-Graff) The cancer diagnosis, a rare sarcoma, was devastating for an old friend of Gordon Mills. “We spent lots of time trying to understand his disease, trying to characterize it, and he went to my colleagues to ask about what was the next therapy for him,” Mills … Read More
(NCI/Rhoda Baer) Expanding treatment options for breast cancer. Enhancing immunotherapy. Addressing disparities in access to cutting-edge treatment. These are some of the highlights from ASTRO, the largest scientific and educational forum for radiation oncology. Members of OHSU’s Department of Radiation Medicine made 11 research presentations and contributed to many more at the annual meeting of the American Society for Radiation Oncology in San Diego.
Polycythemia vera is an uncommon blood cancer that can be controlled with long-established treatments. So it seemed more than a little suspicious to Vinay Prasad, M.D., M.P.H., when the disease took center stage in an episode of “General Hospital” – the longest running daytime drama on American television. “I felt there had to be some backstory,” Prasad, an OHSU Knight Cancer Institute hematologist-oncologist told listeners of the public radio program Think Out Loud. “What we found was … Read More
Aggressive prostate tumors can rapidly evolve to resist PARP inhibitors, but it may be possible to detect resistance early enough to counteract. Two views of the structure of the DNA-repair protein PARP1 It was a surprising discovery that opened up a new avenue for treating prostate cancer. In recent years, studies have revealed that gene mutations long associated with breast and ovarian cancers – BRCA1 and BRCA2 – also play a significant role in driving … Read More
Men with prostate cancer became more vulnerable to falls if they used androgen deprivation therapy, and the heightened risk of falling persisted for more than a year after ending therapy, a study has revealed.
Medicine had never seen anything like it before, Brian Druker, M.D., recalled. “These are people who’d been told to get their affairs in order. And now their blood counts are normal,” the director of the OHSU Knight Cancer Institute told Stat News reporter Bob Tedeschi. “But here’s the problem: When can you celebrate? I felt a little bit like walking on eggshells, because it’s like, OK, is this going to be a flash in the … Read More
In 1997, Oregon became the first state to make it legal for terminally ill patients to self-administer a prescription to hasten death. A review of 991 cases of lethal self-medication through 2015 shows that the law’s impact has remained largely predictable. Three-fourths of the people were dying of cancer, nearly all were white and around 70 percent had attended college. More than 90 percent had health insurance, were receiving hospice care and died at home. … Read More
Scrutinizing the immune cells infiltrating a tumor may reveal the cancer’s vulnerability or resistance to immune-based therapies.